Novel classes of antimicrobials are needed to address the emergence of multidrug-resistant
bacteria such as methicillin-resistant Staphylococcus aureus (MRSA). We have recently
identified pyruvate kinase (PK) as a potential novel drug target based upon it being an
essential hub in the MRSA interactome (Cherkasov, A., Hsing, M., Zoraghi, R., Foster, LJ,
See, RH, Stoynov, N., Jiang, J., Kaur, S., Lian, T., Jackson, L., Gong, H., Swayze, R.,
Amandoron, E., Hormozdiari, F., Dao, P., Sahinalp, C., Santos-Filho, O., Axerio-Cilies, P …